October 27, 2016 1:12 PM ET


Company Overview of Enzo Life Sciences, Inc.

Company Overview

Enzo Life Sciences, Inc. researches, develops, manufactures, licenses, and markets life science research reagents. It offers proteins, antibodies, peptides, small molecules, labeling probes dyes, ELISA kits, natural products, neurochemicals, enzymes, and inhibitors to provide life science researchers tools for target identification/validation, high content and gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. The company also provides DNA, RNA, and protein quantification assays; genomics and general molecular biology tools; molecular labels and probes; compound libraries; and enzymatic, protein, and immunological assays. In addition,...

10 Executive Boulevard

Farmingdale, NY 11735

United States

Founded in 1976





Key Executives for Enzo Life Sciences, Inc.

President of Enzo Biochem Inc
Age: 66
Chief Scientific Officer
Global Head of Marketing
Compensation as of Fiscal Year 2016.

Enzo Life Sciences, Inc. Key Developments

Enzo Life Sciences Reports Unaudited Earnings Results for the First Quarter Ended October 31, 2015

Enzo Life Sciences reported unaudited earnings results for the first quarter ended October 31, 2015. For the quarter, the company reported product revenues of $7.7 million versus $8.0 million last year, a decline of $0.3 million, or 4%. Virtually the entire decline was due to foreign currency headwinds; on a constant currency basis, product sales were even. Operating income for Life Sciences was $7.6 million, which included legal settlements.

Enzo Life Sciences Announces Unaudited Earnings Results for the Third Quarter Ended April 30, 2015

Enzo Life Sciences announced unaudited earnings results for the third quarter ended April 30, 2015. For the quarter, the company reported softer demand combined with the effects of foreign currency resulted in a 9% decline in revenues, to $7.9 million, yet increased 2% from the previous fiscal quarter. During the quarter, foreign currency effect contributed to $0.4 million decline of product revenue. Royalty income declined to $0.4 million or 42% from the prior year period. Operating income totaled $1.0 million, compared to $6.1 million in the prior year period.

Enzo Life Sciences, Inc. Reports Unaudited Earnings Results for the First Quarter Ended October 31, 2014

Enzo Life Sciences, Inc. reported unaudited earnings results for the first quarter ended October 31, 2014. For the quarter, the company reported that product revenues continued to grow as a result of the increased focus on fewer but higher margin products, increasing 4%, to $8.0 million. Operating income totaled $1.6 million, compared to operating income of $1.4 million in the prior year. EBITDA declined to $1.7 million, compared to $2.3 million, a year ago primarily due to lower royalties.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Enzo Life Sciences, Inc., please visit www.enzolifesciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.